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Little is known on long-term outcomes in kidney transplantation. This study evaluated changes and predictors of generic and
transplantation-speciﬁc health-related quality of life (HQoL) over six years in N = 102 kidney transplant survivors using the
Short-form Health Survey-36 and the Transplant Eﬀects questionnaire. Mixed models analysis was used to determine long-term
outcomes. Emotional HQoL improved over time: Mental Component score, Mental Health, Energy (Ps = .000). Physical HQoL
deteriorated: Physical Component Score (P = .001), Pain (P = .002). LRD transplant recipients had greater decline in physical
functioning (P = .003) and PCS (P = .000) compared to cadaver recipients. Worry about the transplant (P = .036) and feelings
of responsibility (P = .008) increased signiﬁcantly over time. Worry about the transplant and perceived ability to work predicted
12.7% and 31.1% in variance in MCS and PCS, respectively. Eﬀorts should be made to maintain HQoL and emotional outcomes
with ongoing monitoring and support programs throughout the course of posttransplant care.
1.Introduction
Kidney transplantation is the treatment of choice forselected
patients with end-stage renal disease (ESRD). Health-related
quality of life (HQoL) has emerged as an important outcome
to quantify the success of transplantation in the long term
[1, 2]. Although HQoL has been systematically assessed
to uniformly document a positive eﬀect of transplantation
(with larger gains in the dimensions of HQoL most aﬀected
by physical health and more modest improvements in areas
aﬀected by psychosocial functioning), there is increasing
recognition that transplantation generates unique demands
and challenges for patients, and families alike [3–5].
The generic HQoL questionnaires provide useful and
important information on the multiple dimensions HQoL
such as functional status, pain, mood and social welfare,
yet they fail to capture issues that are unique to transplant
patients [6]. Issues related to the donation, feelings of guilt,
concerns about viability of graft and uncertainty about the
future have been shown to deﬁne transplantation experience
[7–11] and are hence fundamental to understanding overall
sense of well-being in transplant recipients. This has led
to the development and use of the Transplant Eﬀects
Questionnaire, a validated condition-speciﬁc questionnaire
for the assessment of organ transplant recipients [6, 7, 12,
13].
As graft survival has improved dramatically in last
decades [14] the question of long-term outcomes in kidney
transplantation becomes increasingly important. The pre-
ponderance of literature in patient-reported outcomes in
kidney transplantation to date has focused on early post
operative period [15] or cross-sectional comparisons of
recipients [16] and/or long-term transplant survivors with
their dialysis counterparts [17]. Signiﬁcant associations are
typically found between time elapsed since transplantation
and symptom experience/burden which may compromise2 Journal of Transplantation
adjustment and HQoL. Data on longitudinal changes over
the posttransplantation period are sparse and typically do
not extend to more than 2 years posttransplant [18–20].
Our previous study comparing livings related donor (LRD)
and cadaver tran-plant recipients [7], like many on patient-
reported outcomes in kidney transplantation was cross
sectional which limits conclusions as to the trajectory and
course of transplantation-speciﬁc outcomes between the
two transplant groups. Outcomes focusing on longitudinal
changes in HQoL and Transplantation speciﬁc outcomes are
largely lacking in the literature [21].
There is need for further prospective studies using
generic and transplantation speciﬁc instruments to docu-
ment long-term patient outcomes beyond the immediate
and short term post- transplantation period. There is also a
need to establish predictors of long-term outcomes in this
population.
The current study examines 6-year changes in HQoL
and transplantation-speciﬁc outcomes in a cohort of kidney
transplant recipients. It also compares reported outcomes in
living related donor and cadaver transplant recipients and
explores whether demographics and clinical variables are
predictors of long-term transplantation outcomes.
2.MaterialsandMethods
2.1. Design. This is a prospective study in which a baseline
kidney transplant cohort was reassessed after a 6 years
followup period using the same instruments. (Participants
were only followed up until 6-year from baseline assessment
due to the planned relocation and merging of one of
the transplant units with another renal unit. Thus, it
became diﬃcult, if not impossible, to follow patients’ health
outcomes.)
2.2. Participants. This prospective study evaluated patient-
reported outcomes at two points in time-on an average
of 6 years apart. Kidney transplant recipients from two
transplant centres (Middlesex Hospital and Royal Free
Hospital, London, UK) who participated in a questionnaire
study of HQoL and emotional responses between October
1999 and February 2002 were invited to the followup
study. The study protocol was approved by the Institutional
Review Board and informed consent was obtained from
eachparticipant.Clinicalpracticeandhealthcareprocedures
(post-transplantation followup care and patient support
services) were identical on both hospital sites. There were
no known changes at organizational and health care system
structures during study window.
Target study subjects were the subgroup of kidney
transplant patients from our previous cross-sectional study
[7] who still had functioning grafts. Multiorgan recipients
andrecipientsunder18yearsofageatthetimeofevaluation,
patients who had an acute rejection or infection within a
month of data collection, had dementia, mental illness, or
severe visual/hearing impairment were excluded. Data on
patients who died or lost their graft and were placed back
on dialysis are also not reported in this paper.
2.3. Procedure. Eligible participants were approached by
letter or by the Clinical Nurse Specialist to participate
in the 6-year followup study. Following consent into the
study, participants were requested to undertake a single
assessment conducted by a trained psychologist. Assessment
sessions were scheduled at patients’ convenience with most
assessments coinciding with one of their regular check-up
outpatient appointments.
2.4. Measures. Sociodemographic and medical information
were collected at both time points. These included infor-
mation on age, gender, education level, relationship status
(married/cohabitating relationship or single, separated, wid-
owed), occupation (full/part time or unemployed, retired or
looking after home/family) and ﬁnancial situation (annual
income; change in income categorized as up, down, or
stable). Perceived ability to work was assessed by a single
question developed by Evans et al. [22]: “are you now able
to work full time, part time, or not at all.”
Medical and transplant-related data were extracted from
medical records: primary kidney disease diagnosis, med-
ications (including current immunosuppressive regime),
vintage (time elapsed since renal replacement; time elapsed
since transplant), donor type (cadaver versus living related),
relationship to donor number of infection and rejection
episodes, comorbidities. The presence/absence of seven of
the most common comorbid disorders (plus an “other”
category) was recorded. These included diabetes mellitus,
hypertension, ischaemic heart disease, peripheral vascular
disease, cancer, bone diseases and chronic obstructive air-
ways disease. All these socioeconomic and clinical param-
eters were considered both in terms of baseline levels and
change over the followup period. For each variable a change
score was calculated comparing the data at followup with
that at baseline. Changes in these clinical variables were
deﬁned as improving, static, or worsening with the static
group being treated as the reference group.
Charlson Comorbidity Index (CCI) was also computed
to quantify comorbid illness. CCI scores were calculated
using the method previously described by Beddhu et al. [23].
Laboratory data were also recorded (eGFR). Glomerular
ﬁltrationrate(GFR)wasmeasuredfollowingtheintravenous
administration of 3MBq 51Cr-EDTA diluted to 10mL on
0.1%w/v excess EDTA solution [24].
Transplantation-speciﬁc emotional and behavioural out-
comes were measured using the Transplant Eﬀects Ques-
tionnaire (TxEQ) [6]. The 23-item TxEQ contains ve sub-
scales that assess worry about the transplant; feelings of guilt
towards the donor, disclosure of transplantation medication
adherence and perceived responsibility to do well. Subscale
scores are expressed as a mean by dividing the total score
by the number of items, hence ranging from 1 to 5. Higher
scores signify more worry about the transplant, more guilt,
more disclosure, more perceived responsibility, respectively,
andgreateradherence.Thequestionnairehasdatatosupport
its internal structure and factorial validity and has been
found to have acceptable internal consistency, test–retest
reliability and face validity [6].Journal of Transplantation 3
HQoL was measured with the 36-item Medical Outcome
Study Short Form Health Survey (SF-36) [25]. The UK
version 2 of the SF-36 was used to ensure face validity and
maximize acceptability in British participants [26]. The SF-
36 is a generic multidimensional measure of HQoL that
contains eight sub-scales representing physical functioning
(PF), social functioning (SF), role limitations due to physical
health problems (RPh), role limitations due to emotional
problems (REm), mental health (MH), vitality (VT), bodily
pain (BP) and general health perceptions (GH). Sub-scales
scores range from 0–100 with higher scores indicating
better HQoL. In addition, summary scores were calculated
for physical (PCS) and mental (MCS) components [27].
To facilitate interpretation and comparisons to the norms,
normative-based scoring was used [27]. Normative-based
scoring involves a linear t-transformation to ensure that all
SF-36 sub-scales and summery scores had a mean of 50 and
aS Do f1 0i nt h eg e n e r a lU Kp o p u l a t i o n[ 28]. The SF-36 has
been proved reliable and valid in various demographic and
patient populations including ESRD and transplant patients
[29, 30]. A diﬀerence of ﬁve-points in a particular dimension
is considered a minimal clinically signiﬁcant change [31].
Patients’ levels of functional ability to perform activities
of daily life was determined by the Karnofsky performance
status [32] completed by Transplant nurses. Scores range
from 0–100 with 0 indicating death and 100 indicating full
capacity to perform normal activity. In general scores 50–70
represents an individual who requires additional assistance
and inability to work and a score lower than 50 represents
needs for hospitalization, nursing care or institutionalization
[32–34].
2.5. Statistical Analysis. Data analyses were performed using
Statistical Package for Social Sciences statistical software for
windows (Version 17.0; SPSS Inc., Chicago, IL). Descriptive
statistics were performed as appropriate, depending on
measurement level and distribution of the data for the
sample population and the subgroups. Analyses of variance
were performed to test between-group diﬀerences, and
general linear models for repeated measures assessed intra-
individual eﬀects for the study cohort. Trajectories of change
(improvement; deterioration; stable) were also calculated
to examine change in HQoL in individual participants.
Classiﬁcation was based half SD (5 points) to determine
signiﬁcant change [31, 35].
Inferential statistics included Pearson’s or Spearman’s
correlations (as appropriate), cross tabulations, chi-square,
or Fischer’s exact test to investigate the impact of relevant
variables (absolute baseline and change scores) on HQoL.
Hierarchical multiple regression analyses were used to ana-
lyze predictive HQoL variables. Variables were entered into
the regression model when a signiﬁcant relationship using
bivariate analyses was detected. Baseline levels were included
as predictors under forced entry in ﬁrst step. The level of
signiﬁcance was set at P less than .05.
3. Results
3.1. Study Population. A total of 102 out of 172 (59.3%)
eligible transplant survivors from the original cohort [7]
participated in the six-year followup assessment at a mean
interval of 76.48 (7.28) months since baseline assessment.
Transplantvintage,thatis,timeelapsedsincetransplantation
at study entry/baseline, was 8.08 (SD = 6.89) years.
Nineteen patients (N = 19) refused to participate
because of frail/poor health, N = 16 due to time commit-
ments,N = 16duetoburdenof workinvolved ordisinterest;
N = 6 were undecided, and n = 2w e r eu n a b l et ob er e a c h e d
in listed contact numbers/addresses or at their scheduled
hospital appointments during the study window.
Patient survival was 87.8%, and transplant survival
was 85.3% in the study period. Mortality was due to
cardiovascular reason/events (N = 27), malignancy (N =
7), and other causes (N = 5). Cumulative 6-year rates of
infection episodes were .08 (1.2) per patient. A total of N =
38 of patients who lost their transplant were treated with
hemodialysis, N = 13 were on peritoneal dialysis regimes
and N = 11 patients were attending low clearance clinic
(Stage 3–5 chronic kidney disease).
The paper reports ﬁndings on the transplant survivors
(see Figure 1 for information of the cohort). The mean age
of this group was 46.57(14.21) years; 58.8% of patients were
males and most were cadaver transplant recipients (79.4%).
Immunosuppressive medications were cyclosporine
(63.7 %) or tacrolimus (32.3%), mycophenolate mofetil
(7.8%) and/or azathioprine, 34.3%), and steroids reﬂecting
the state of the art immunosuppression when these patients
were transplanted.
Demographic and medical information showed few
diﬀerences between responders and nonresponders. Non
responders had lower Karnofsky score (P = .042) and
reported more comorbid conditions (P = .023), albeit there
were no diﬀerences in Charlson Comorbidity Index scores or
comorbiditiesdiagnosesabstractedthroughmedicalrecords.
All other socioeconomic parameters (e.g., gender, income,
work, and relationship status) and clinical markers (e.g.,
GFR, source of transplant, total ESRD time or transplant
vintage, rejection episodes, hospitalisation days) were com-
parable between responders and non responders. Table 1
details the baseline demographic and clinical characteristics
of the study sample and two transplant subgroups.
Socioeconomic and clinical parameters remained largely
unchanged across assessments. Relationship status for N =
85 (83.3%) patients was unchanged across the two assess-
ments, N = 9 (8.8%) respondents reported having lost their
spouse/partner through divorce or widowing and N = 4
(3.9%)reportedchangefromsingle/divorceestatustogetting
married or being in a cohabiting relationship at the 6-year
followup.
A total of 19 patients reported changes in employment
status with N = 12 (12.2%) patients who were employed at
baseline, no longer being employed at followup and N = 7
(7.1%)patientswhowerenotemployedatbaselineresuming
work. The vast majority had no change in occupational
details (N = 74; 80.4%).
Perceived ability to work remained unchanged in N =
75 (76%), N = 6 (6%) respondents downgraded ability to
work and N = 18 (18%) reporting improvements in ability
to work from baseline to 6-year followup.4 Journal of Transplantation
Transplant baseline
cohort
Died before 6 years A l i v ea t6y e a r s Untraced
Dialysis Transfer to diﬀerent Transplant
Eligible TX Non-eligible
(stroke, visual/
hearing impairment,
active malignancy)
Final Sample
N = 347
N = 39 N = 280 (80.7%) N = 28(8.1%)
N = 51(18.2%)
Hospital/ Tx unit
N = 36 (12.9%) N = 182 (65%)
N = 161 (91.3%)
N = 21 (11.5%)
N = 102 (63.3%)
Stage 3-5 CKD N = 11 (3.9%)
Figure 1: Study cohort.
Likewise income was undiﬀerentiated in vast majority of
respondents(N = 61(89.2%)ofrespondents),N = 1(1.5%)
reported lower income and N = 6 (9.2%) reported higher
income at followup compared to baseline.
Rates of comorbid conditions (i.e., diabetes mellitus,
hypertension,ischemicheartdisease,peripheralvasculardis-
ease, cancer, bone diseases and chronic obstructive airways
disease) were comparable across assessments; mean GFR
levels were signiﬁcantly lower at 6-year followup reﬂecting
process of chronic rejection (mean GFR at followup = 35.5,
SD = 16.8; F = 3.42, P = .04).
3.2. Patient Outcomes: HQoL and TXEQ. The observed SF-
36 scores across assessments were comparable to those in
general population (within 1 SD of norms; normative mean
= 50; SD = 10) with the exception of the physical functioning
and general health perception scores which were slightly
lower than 1 SD below population norms.
Our ﬁrst research question was whether patient reported
outcomes changed over time.
Repeated measures ANOVAs revealed signiﬁcant dif-
ferences in 6 of 10 SF-36 scores (See Table 2). Physical
HQoL declined from baseline to 6-year followup: physical
component score (F = 14.87, P = .001), Pain (F =
10.04, P = .002). Emotional HQoL indicators on the other
hand signiﬁcantly improved over time: mental component
score (F = 16.64, P = .000) mental health (F =
41.49, P = .000), vitality (F = 13.54, P = .000); the only
exception being role-emotional which was worse at followup
assessment (F = 4.49; P = .037).
Signiﬁcant diﬀerences over time were found for two
of TXEQ subscales with worry about graft viability (F =
4.52,P = .036) and perceived responsibility to do well
increasing over time (F = 7.34,P = .008).
As time since transplantation was varied, analyses were
repeated using transplant vintage at study entry (baseline)
as a between-subject factor to compare outcomes in patients
who had their graft for less than 2 years (19.6%; N = 20)
with those who had their grafts between 2–5 years (22.5%
(N = 23) and those with more than 5 years post-transplant
57.8% (N = 59). Results replicated the same pattern of
changes in SF-36 and TxEQ scores in all subgroups with the
exception that there were no signiﬁcant changes across time
in role limitations due to emotional problems (P = .18).
There were no signiﬁcant group or interaction eﬀects in any
of the outcomes suggesting that transplant vintage had no
eﬀect on the study outcomes across time.
3.2.1. Patterns of Intraindividual Change in HQoL. To eval-
uate patterns of intra-individual change the two summary
HQoL scores (physical component score; mental component
score)andfrequenciesofpatternswereanalyzedfortheslope
between time points (from baseline to 6 years): worse (scores
at followup ≤ 5 points, i.e., 0.5 SD than baseline), improved
(scores at followup ≥ 5 points, i.e., 0.5 SD than baseline),
stable (scores at followup within ±4.99 points of baseline).
The 0.5 SD was used as this represents the minimally clinical
signiﬁcant diﬀerence [31, 33].
When evaluating the breakdown of participants into the
3p a t t e r n sw i t hr e s p e c tt op h y s i c a lc o m p o n e n ts c o r e ,N = 23
(30.7%) had no change in physical component score,N = 40
(53.3%)worsened,andN = 12(16.0%) improvedovertime.
Similar analysis on mental component score scores
revealed that N = 34 (45.3%) had no change in mental
component score, N = 25 (33.3%) worsened, and N = 16
(21.3%) improved.
ANOVAs followed by post hoc comparisons indicated
that patients who reported improvements on physical com-
ponent score scores have had their grafts for longer (mean
= 11.01; SD = 2.46) compared to the no change physical
component score group (mean = 4.92, SD = 4.71) (F =
7.34, P = .011).
T h eo n l yv a r i a b l et od i ﬀerentiate between the mental
component score groups was TXEQ worry change scores.Journal of Transplantation 5
Table 1: Sociodemographic and clinical characteristics of study sample.
Total sample (N = 102) Cadaver transplant (N = 81) LRD transplant (N = 21) P value
M (SD)/% (N) M (SD)/% (N) M (SD)/% (N)
Age (years) 46.57 (14.21) 48.22 (14.67) 40.43 (10.57) .025
Age (years) at diagnosis 31.18 (16.99) 32.81 (17.82) 25.04 (11.85) ns
Education (years) 12.13 (4.46) 11.87 (4.80) 13.04 (2.94) ns
Gender (% female) 41.2% (42) 39.5% (32) 47.6% (10) ns
Ethnicity (% white) 76.5% (78) 75.3% (61) 81.0% (17) ns
% married/cohabitating relationship 62.7% (64) 60.5% (49) 71.4% (15) ns
% employed (f/t; p/t) 64.7% (66) 60.5% (49) 81.0% (17) ns
% able to work 76.5% (78) 74.1% (60) 85.7% (18) ns
Income .012
£0–10,000 16.7% (17) 18.5% (15) 9.5% (2)
£10,001–20,000 24.5% (25) 28.4% (23) 9.5% (2)
£20,001–30,000 15.7% (16) 13.6% (11) 23.8% (5)
> £30,000 21.6% (22) 14.8% (12) 47.6% (10) ns
% Diabetes 6% (6) 6.1% (5) 4.7% (1) ns
% Vascular disease 21.5% (22) 22.5% (18) 19% (4) ns
% Hypertension 67.6% (69) 67.9% (55) 66.6% (14) ns
GFR 43.83 (20.47) 43 (20.22) 45.77 (22.14) ns
Transplant vintage (years) 8.08 (6.88) 11.87 (4.80) 11.25 (5.90) .017
Primary kidney disease diagnosis (% yes)
% GN 14.7% (17) 17.2% (14) 14.3% (3)
% APKD 11.8% (12) 12.3% (10) 9.5% (2)
% Reﬂux Nephropathy 8.8% (9) 9.8% (8) 4.76 % (1)
% Diabetes 4.9% (5) 6.2% (5) 0% (0)
% hypertension 13.7% (14) 16% (13) 4.6% (1)
% All Other 44.1% (45) 38.3% (31) 66.6% (14)
RRT: renal replacement therapies; f/t: full time; p/t: part time; ESRD-SI: end-stage renal disease severity index; GFR: glomerular ﬁltration rate; GN:
glomerulonephritis; APKD: adult polycystic kidney disease.
†P values indicate signiﬁcance of diﬀerence between CAD and LRD samples in the respective sociodemographic variables. ANOVA or Chi-square tests were
used as appropriate.
Post hoc comparisons indicated that patients whose emo-
tional HQoL (i.e., mental component score) worsened
experienced increased worry about the viability of their graft
(mean worry change score = 2.18, SD = 4.92) compared to
patients whose mental component score improved (mean
worry change score = −2.50, SD = 7.39) (F = 5.35, P =
.027).
3.3. Outcomes across Time between Cadaver and Living
Related Transplant Recipients. Comparisons of outcomes by
transplant source showed that HQoL levels were comparable
for the two transplant groups with the exception of physical
functioning and physical component scores.
Repeated measures ANCOVAs controlling for casemix
diﬀerences (i.e., age, income and duration of transplant)
indicated signiﬁcant interaction eﬀects in physical function-
ing (F = 7.07; P = .009) and physical component score
(F = 6.03, P = .017).
Post hoc tests showed that LRD transplant patients had
higher physical functioning score and physical functioning
scores at baseline compared to cadaver transplant (F =
5.72, P = .019, and F = 8.13, P = .005, resp.) but
followup scores were equivalent. Within-groups post hoc
tests showed that physical functioning declined signiﬁcantly
from baseline to 6-year followup in the LRD transplant
group (F = 9.34, P = .007) whereas scores for cadaver
transplant recipients remained unchanged (see Figure 2(a)).
Physical component scores diminished in both trans-
plant groups, yet the decrease was greater in LRD transplant
patients (see Figure 2(b)).
A signiﬁcant transplant type by time interaction eﬀect
was also found for disclosure (F = 4.817, P = .031). Post
hocs tests revealed no group diﬀerence in absolute value
between cadaver and LRD transplant recipients; yet LRD
transplant recipients reported a nearing-signiﬁcant increase
in disclosure behaviours over time (F = 4.20, P = .055)
whereas levels of disclosure remained unchanged in cadaver
transplant patients (F = .003,P = .959).
3.4. Factors Associated with Tx-Speciﬁc and
Generic HQoL Outcomes
3.4.1. Factors Associated with Tx-Speciﬁc Outcomes. Correla-
tion analysis between sociodemographic, medical variables6 Journal of Transplantation
Table 2:Patientreportedoutcomesatbaselineand6-yearfollowup:totaltransplantsample;Cadavertransplantandlivingrelatedtransplant
recipients.
CAD TX LRD TX Total Sample
P value T1 T2 T1 T2 T1 T2
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
SF-36
MCS 45.84 (6.72) 50.82 (11.05) 43.50 (4.69) 49.73 (8.35) 45.30 (6.36) 50.57 (10.45) .000
PCS 44.93 (12.30) 41.84 (12.29) 51.40 (7.15) 39.80 (14.70) 46.41 (11.61) 41.37 (12.80) .001
PF 38.89 (16.91) 38.55 (16.47) 50.73 (6.21) 41.46 (13.79) 41.28 (16.06) 39.14 (15.94) ns
RPh 45.88 (9.53) 45.06 (10.37) 51.14 (4.68) 46.73 (8.83) 46.94 (9.00) 45.39 (10.05) ns
Rem 50.50 (6.88) 48.36 (10.01) 52.60 (4.17) 50.56 (7.10) 50.93 (6.45) 48.81 (9.49) .037
SF 40.14 (10.38) 39.62 (14.65) 45.90 (7.27) 45.62 (11.24) 41.34 (10.06) 40.87 (14.17) ns
MH 41.65 (9.19) 49.47 (12.59) 42.44 (5.67) 51.52 (9.36) 41.84 (8.54) 49.91 (11.96) .000
VT 44.65 (7.18) 48.97 (10.92) 43.83 (6.09) 45.86 (10.24) 44.47 (6.94) 48.30 (10.80) .000
BP 48.11 (11.40) 45.14 (13.15) 52.89 (8.29) 44.70 (13.91) 49.11 (10.95) 45.05 (13.24) .002
GH 43.01 (11.55) 41.29 (13.14) 43.51 (10.04) 39.54 (9.72) 43.11 (11.21) 40.94 (12.51) ns
TxEQ
Worry 3.03 (.88) 3.25 (.71) 3.07 (.87) 3.30 (.77) 3.04 (.87) 3.26 (.72) .036
Guilt 2.13 (.60) 2.25 (.78) 2.61 (.74) 2.55 (.73) 2.23 (.66) 2.32 (.77) ns
Disclos 3.95 (.82) 3.96 (.99) 3.59 (1.15) 4.05 (1.04) 3.88 (.90) 3.98 (.99) ns
Adherence 4.30 (.71) 4.28 (.76) 4.19 (1.11) 4.00 (1.00) 4.27 (.81) 4.22 (.82) ns
Responsibility 3.72 (.71) 3.97 (.85) 3.71 (.74) 3.96 (.76) 3.72 (.71) 3.97 (.83) .008
CAD: cadaver; TX: transplant; LRD: living related donor; T1: baseline; T2: 6-year followup; GH: general health; PF: physical functioning; BP: bodily pain; VT:
vitality; RPh: role limitations due to physical problems; REm: role limitations due to emotional problems; SF: social functioning; MH: mental health; MCS:
mental component score; PCS: physical component scores; TXEQ: Transplant eﬀects questionnaire; Disclos: disclosure.
†Normative based scoring: In all SF-36 sub-scales the general population mean is 50 and 10 is a standard deviation.
††P value reported based on repeated measure ANOVAs conducted on total sample.
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Figure 2
and TxEQ sub-scales (absolute scores at followup) showed
that increasing age was associated with less worry regarding
the transplant (r =− .24,P = .023), more disclosure (r =
.25,P = .019) and more perceived responsibility to do well
(r = .22,P = .036) at the 6-year followup.
Feelings of worry about the graft at followup were
signiﬁcantly higher in patients who perceived themselves as
ableoffullorparttimeemployment(mean =3.33,SD = .70)
compared to patients who identiﬁed themselves as unable to
work (mean = 2.95, SD = .80) (F = 3.97, P = .049).
Caucasian patients reported higher levels of disclosure
about their transplant (mean = 4.08, SD = .95) than patients
of other ethnic groups (mean = 3.55, SD = 1.17) (F =
4.47, P = .037).
Only transplant vintage and perceived work ability were
signiﬁcantly associated with TXEQ change scores. LongerJournal of Transplantation 7
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transplant vintage was associated with greater increase in
feelings of guilt (r = .28, P = .008) and in feelings of
responsibility across time (r = .27,P = .011).
Increase in worry about the transplant was greater in
patients who perceived themselves to be capable of part or
full time work (mean worry change score = 2.09, SD = 5.14)
relative those who reported being unable to work (mean
worry change score = −2.71, SD = 7.31) (F = 8.73, P =
.004).
Signiﬁcant associations were also found between the
TXEQ sub-scales (absolute and change scores). Stronger
feelingsofguiltweresigniﬁcantlycorrelatedwithmoreworry
about the transplant (r = .45, P = .001), higher perceived
responsibility (r = .43,P = .001), and lower disclosure
(r =− .43,P = .001). Feelings of responsibility to do well
were positively associated with worry about the transplant
(r = .35, P = .001) and adherence levels (r = .28, P =
.006).
Guilt change scores were positively correlated with
concomitant changes in worry (r = .39, P = .001) and
responsibility (r = .30;P = .004), and negatively correlated
with changes in disclosure (r − .32, P = .002). Worry about
transplant change scores were also correlated with change
scores in responsibility (r = .27,P = .015).
3.4.2. Factors Associated with HQoL at Followup. No signif-
icant associations were found between HQoL and gender,
ethnicity or measures of illness severity (haemoglobin levels,
duration of dialysis prior to transplantation, time since
transplantation) (data not shown). However, there were sig-
niﬁcantassociationsbetweennumberofcomorbidities/long-
standing illnesses, age, work status, perceived work ability,
income, relationship status, Karnofsky scores and physical
HQoL at followup in the expected direction (see Table 3).
GFR was signiﬁcantly associated with mental component
score.
Signiﬁcant associations were also found between worry
about transplant and lower emotional HQoL at followup:
mental component score, social functioning, mental health,
vitality, and general health perception with correlation
coeﬃcients ranging from r =− .30 to r =− .27 (P ≤
.014). Disclosure shares a positive correlation with role-
emotional (r = .24, P = .024), adherence to medication
with Mental Component Score (r = .25, P = .029).
Feelings of responsibility were negatively associated with
physical component score, physical functioning and social
functioning (see Table 3).
Univariate analyses on HQoL and TXEQ change scores
revealed several signiﬁcant associations: increased worry
about viability of graft was associated with reduction in
physical component score (r =− .32, P = .008), role
physical (r =− .35, P = .004), role-emotional (r =
−.32, P = .004), social functioning (r =− .45, P = .000),
mental health (r =− .31, P = .006), bodily pain (r =
−.24, P = .028), vitality (r =− .297, P = .008), general
health perception (r =− .47, P = .000), indicative of
worse HQoL across time. Increase in guilt is related to role-
emotional reduction (r =− .24, P = .028), and increase
in adherence to medication is associated to a reduction in
physical functioning (r =− .23, P = .040).
HQoL changes were associated with income, perceived
work ability, and relationship status in that HQoL losses
were greater in the disadvantaged socioeconomic groups:
low income and role-physical and social functioning (F =
4.11, P = .046; F = 7.03, P = .010, resp.); not able to
work and role-emotional (F = 4.63; P = .036), social
functioning (F = 8.47, P = .005) and mental component
score (F = 7.32, P = .004), not in marital or cohabiting
relationship(i.e.,widowed,singleordivorced/separated)and
social functioning (F = 6.76, P = .011) and bodily pain
(F = 5.20, P = .025).
3.5. Predictors of Generic Hqol Outcomes. Hierarchical multi-
ple regression analyses were conducted to identify predictors
of HQoL at 6-year followup. The variables selected for these
analyses were those associated with physical component
score and mental component score (absolute and/or change
scores) in the univariate analyses at P<. 05. Baseline levels of
HQoL were entered ﬁrst followed by sociodemographic clin-
ical and psychological variables. Analyses were subsequently
repeated using PCS and MCS change scores as the dependent
variables.
The results indicated that baseline physical component
score (beta = .353, P = .014), worry about transplant (beta
= −.30, P = .025), and perceived ability to work (beta =
−.294, P = .039) were signiﬁcant predictors of absolute
physical component score at followup accounting for R2
= 36% (AdjR2 31.1%) of variance. When variables were
regressed on physical component score change scores the
only signiﬁcant predictor was worry change scores (beta =
−.384, P = .012) explaining R2 = 14.7% (AdjR2 = 12.6%) of
c h a n g e si np h y s i c a lH Q o Lo v e rt i m e .
The regression model to predict mental component
change scores in the combined transplant sample indicated
that only perceived ability to work was signiﬁcant (beta =
−.442,P = .003),accountingforR2 =19.5%(AdjR2 =17.5%)
in mental component changes scores. Perceived work ability
(beta = −.299, P = .026) and worry about transplant (beta =
−.265, P = .043) were signiﬁcant in the regression to predict
absolute MCS at the followup jointly explaining R2 =15.9%
(AdjR2 = 12.7%) of the variance.
4. Discussion
It has been long established that HQoL of transplant recip-
ients improves from before to after receipt of the TX graft
[1, 36, 37]. Previous studies have suggested that organ TX
patientsmayreachaplateauat1-2yearspost-transplantwith
anticipated downturns thereafter but empirical evidence is
lacking [19]. This study provides unique longitudinal data
on the patient reported outcomes in kidney transplantation
extending time frame of the analyses beyond the ﬁrst 2 years
posttransplantation.
Study ﬁndings showed that the widely documented
HQoL improvements pre- to post-transplantation [1, 38]
cannot only be sustained but in some domains improved
further over a much longer period. Our data indicateJournal of Transplantation 9
that decline in HQoL is not an inevitable consequence of
long-term condition or advancing illness in the context
of kidney transplantation—there is a small shift towards
worsening of overall physical HQoL and domains most
aﬀected by health such as pain and physical functioning yet
emotional dimensions of HQoL and vitality show marked
improvements over time.
Mean HQoL levels for combined sample and for both
TX groups remained within 1 SD of general population
norms at the followup yet individual HQoL trajectories were
variable. Analysis of individual patterns showed diﬀerences
in trajectories of change with 50% and 25% of transplant
recipients reporting substantial decline of at least 5 points
from baseline levels in physical component score and mental
component score, respectively, indicating that group analysis
may mask considerable interindividual variation in long-
term outcomes.
Although it may be tempting to attribute the observed
changes to normal aging, studies of HQoL in cohorts of
nonmedical community populations show HQoL across
domains of physical and psychological health as well as
emotional and social role functioning do not deteriorate
substantially with aging but remain stable [39, 40]. Age was
also not signiﬁcantly associated with HQoL changes in this
study. The deterioration in physical functioning, and role
limitations levels over the 6-year window may be related
to the chronic immunosuppressed state and the physical-
and health-related consequences of long-term immunosup-
pression [41–43]. Physical HQoL impairments may also be
related to incidence of diabetes which in renal transplant
recipients as opposed to other transplant recipients is an
end-organ/morbidity imposing disease rather an additional
complication [44]. As such it may limit posttransplantation
improvement or lead to physical HQoL reduction in renal
recipients. As the number of diabetic patients in our sample
wasverysmall,thequestionofdiﬀerentialoutcomestrajecto-
ries between patients with and without diabetes could not be
examined.
The decline in physical dimensions functioning was evi-
dent in both transplant groups, yet the slope of deterioration
was markedly greater for the LRD transplant recipients.
The pronounced reduction of physical well-being in LRD
transplant group is clearly noteworthy as clinical outcomes
for these patients tend to be superior to those of cadaveric
transplantation [45, 46]. Previous cross-sectional studies
have reported comparable HQoL among transplant groups
[7, 47], yet our longitudinal data suggest that physical HQoL
is better preserved in CAD transplantation compared to
LRD transplantation. Our data showed that physical HQoL
in LRD transplant recipients is signiﬁcantly higher than
that of cadaver counterparts at baseline but diminishes
dramatically over time to reach equivalent levels of those
cadaver transplant patients at 6-year followup assessment. It
is not clear what may be driving this diﬀerential pattern of
changes over time in the two transplant groups.
The ﬁndings albeit limited due to small numbers of LRD
transplant patients suggest that a major area of improvement
in transplant care is to preserve the physical HQoL beneﬁts
derived early on for this patient group. Although routinely
the clinical care focuses mainly on adjustment of immuno-
suppression, prevention of complications, greater empha-
sis is needed on functional outcomes and rehabilitation
throughout post-transplant care and beyond the immediate
or early posttransplantation period.
Anotherimportantﬁndingisthatdespitephysicalquality
of life declines, emotional well-being/ HQoL improved over
time. Mean scores in mental health for instance, increased
by nearly 1 SD from baseline to 6-year followup. These
results contrast with ﬁndings of increased rates in anxiety
and depressive disorders in kidney transplant recipients [48,
49] although the HQoL data was not designed to diagnose
emotional disorders or measure speciﬁc emotions.
Despite the emotional HQoL gains, study ﬁndings indi-
cate that patients may still have emotional needs/concerns.
Worry about viability of the graft remained prominent in
transplant recipients and increased signiﬁcantly over time in
line with the worsening physical HQoL evaluations.
Late kidney graft loss remains a signiﬁcant problem
and hence patients increased feelings of worry about graft
viability may reﬂect their awareness of the reality of ﬁnite
graft function [50, 51]. Although clinical events or illness
severity were not related to increased worry in this study
it still remains likely that worry may be fuelled either
through patients’ direct experience of complications, bouts
of ill health (not necessary related to renal condition) or
vicariously when being informed of graft loss or death of
other transplant patients. As shown in other settings [52]
these indirect experiences can have a profound eﬀect on
surviving patients which may explain the increasing level of
worry on one hand and improved emotional well being as
patients may attach more signiﬁcance and appreciate more
their prolonged graft survival in the face on unpredictability
of post-transplantation course.
The concomitant increase in worry about transplant
viability and perceptions of responsibility to do well may
suggest patients’ resolve/determination to exert some control
over graft uncertainty and unpredictability of prognosis or
likely recurrence of underlying renal disease. It may be that
perceptions of responsibility are acting as approach directed
coping to maintain emotional morale and try to live up
to expectations while putting fears and uncertainty behind
them/aside.
It is also of note that worry about transplant was
associated with both absolute and HQoL change scores,
albeit, eﬀect sizes were small. Patients whose HQoL declined
alsoreportedmoreworryabouttransplant.Attentionshould
be particularly directed towards monitoring these concerns
amongst the younger transplant recipients who appear to
be more preoccupied/troubled with such concerns. Older
patients reported lower levels of worry about transplant at
followup despite worsening physical HQoL [53]. Interven-
tions based on psychotherapy principles have been shown
to be eﬀective in addressing emotional issues in transplant
recipients [9, 54].
The important question on predictors of HQoL changes
in the kidney transplant population remains largely unan-
swered. We took into consideration several potential expla-
nations for these ﬁndings but overall variance explained was10 Journal of Transplantation
fairlysmall—importantly,anumberofillnessandsocioemo-
tional variables albeit signiﬁcantly associated with absolute
HQoL scores consistent with previous cross sectional work
[7, 42, 53, 55] were not consistently or reliably associated
with the change in physical component score and mental
component scores in the multivariate analysis. This clearly
highlightstheneedformorelongitudinalresearchtoidentify
what drives changes in HQoL in this population.
It is also important to recognize that there may other
plausible explanations for the HQoL changes not explored
in this study. Unmet expectations (discrepancy between
health expectations and health experiences) are thought to
adversely impact HQoL [56]. transplant patients may have
high or even unrealistic expectations for life after kidney
transplantation or even view their transplant as cure for
their condition which may lead them to under rate physical
HQoL and functional outcomes especially when complica-
tions or limitations are imposed or when rehabilitation or
functionality related goals are not fully achieved. Further
research is needed to examine patients’ expectations on
transplantation in the context of ESRD and to explore their
role in determining immediate and long-term HQoL and
emotional outcomes in kidney transplantation.
We acknowledge several limitations in this prospective
observational study. First, even in longitudinal investigations
issues of causality cannot be established with certainty
as the ﬁndings remain associational in nature. In the
absence of an experimental design, alternative explanations
for the observed associations such as reverse causality and
bidirectionality cannot be ruled out. Study participants were
not assessed at a uniform post-transplant time although the
time interval between assessments was ﬁxed. However, to
determine/control for the inﬂuence of years post-transplant,
it was included as an independent variable in the analyses
but shown no signiﬁcant association with outcomes at
followup. It is important to note that, as it was not
deemed possible to conduct repeated sequential assessments,
future prospective research would beneﬁt from further
methodological improvements such as including planned
regular assessments of general and transplantation-speciﬁc
outcomesatﬁxedtimepointsthroughouttheearlyandlong-
term post-transplantation period.
The overall attrition rate may have resulted in a biased
sample. This is partly due to the high turnover of transplant
patients; with N = 38 patients being transferred out of our
transplant unit and N = 36 not been traced at the 6-year
of followup. Part of attrition was due to poor health with
N = 21 patients refusing participation citing frail health,
mobility issues or being overwhelmed with unresolved
health issues which may have led to underestimation of
magnitude of quality of life eﬀects over the posttransplant
period.
Related to this, the sample size for the LRD transplant
group was fairly small which may have undermined study
power to detect signiﬁcant diﬀerences between LRD and
Cadaver renal transplant recipients. The study exclusion
criteria of the present study may limit the generalizability of
the results to the kidney transplantation population at large
(i.e., individuals with psychosis, acute illness, neurological
disease and other major organ, failure were not included in
this study).
Finally, caution is also warranted in interpreting study
ﬁndings as P values were not adjusted for multiple com-
parisons, thereby resulting in inﬂated Type I error rate. The
strategy adopted in this article was to be exploratory and to
capitalize on chance ﬁndings to have greater certainty that
no signiﬁcant eﬀects were overlooked [57]. Our discussion
focuses mainly on signiﬁcant ﬁndings (P ≤ .01). This
highlights the need for further research to attempt to
replicate or refute these ﬁndings.
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